The 340B Rebate Pilot Program turns the traditional 340B discount into a post-purchase rebate for select drugs, and plan sponsors need to assess how this shift may affect their pharmacy spend and oversight obligations. I suggest engaging with your PBM and reviewing contract language now.
What it is and why it was created
Launched by the Health Resources & Services Administration (HRSA) via a notice effective August 1 2025, the pilot invites manufacturers to offer rebates instead of upfront discounts under 340B for certain drugs tied to the Medicare Drug Price Negotiation list. (1)
The policy aims to address concerns over diversion, duplicate discounts and lack of timely claims-level data by requiring claim-data submissions before the rebate is paid. (2)
For plan sponsors and self-funded employers, the change matters because the financial mechanics and cash-flow for covered entities may shift and that may indirectly impact plan costs, especially if hospitals or other covered entities adjust pass-through pricing or contract pharmacy arrangements.
What it means for key stakeholders
Manufacturers They gain an option to provide 340B benefits via rebates rather than upfront discounts, which can improve visibility into how drugs are used under 340B and may reduce exposure to duplicate discounts. (3)
Action: Manufacturers will need to build IT platforms, collect multiple fields of claim data, and issue rebates within 10 calendar days of claim submission. (4)
PBMs/GPOs PBMs and group-purchasing organizations may face new operational overlays: verifying eligible claims, coordinating with wholesaler-accounts, and tracking rebate flows. The shift could affect how rebates are captured, passed along or retained.
Action: Review PBM contracts and audit pass-through language; ensure transparency of rebate disbursement mechanisms.
Plan Sponsors / Self-Funded Employers Your hospital or health system suppliers may in turn modify contract pharmacy flows, pricing structures, or pass-through arrangements under this pilot. Any disruption in discount pass-through could bounce back into plan cost.
Action: Request visibility into 340B-related rebates and contract pharmacy pricing with TPAs and PBMs now. Insert auditing language on 340B rebate mechanisms in vendor contracts.
Patients While covered entities retain the 340B benefit in theory, patients may feel indirect effects: if cash-flow or administrative burden on covered entities increases, there could be pressure to shift service settings or pharmacy sites. Some safety-net providers warn the rebate-model may strain operations. (5)
Action: Monitor patient access trends at your network pharmacies or contract pharmacy settings tied to 340B-entities.
Three key takeaways
- The pilot makes upfront discounts into post-purchase rebates for select drugs under 340B, shifting cash-flow and requiring more claims-level data.
- Plan sponsors should review and update contracts with PBMs/TPAs to preserve pass-through of 340B benefit and gain audit rights.
- Early engagement and oversight on data workflows, claim submissions and vendor processes will protect your plan from hidden cost migration.
Conclusion and CTA This pilot isn’t about accusing anyone; it’s about staying ahead of a shift in how 340B savings might flow and ensuring the fiduciary standard of care for your health plan. If you’d like help unpacking your contracts, drafting data requests or assessing vendor readiness, let’s start that conversation.
References
- HRSA. “340B Rebate Model Pilot Program.”
- Frier Levitt. “340B Alert: What You Need to Know About HRSA’s Rebate Pilot Program.”
- Milliman. “340B Rebate Model Pilot Program—Medicaid implications and readiness.”
- VytlOne. “HRSA 340B Rebate Model Pilot Program FAQs.”
- Becker’s Hospital Review. “HRSA launches 340B rebate pilot with 8 drugmakers: 5 things to know.”
Elevate your expertise in pharmacy benefits management with the Certified Pharmacy Benefits Specialist® (CPBS) program. Whether you’re an HR leader, finance executive, consultant, or pharmacist, this certification provides the in-depth knowledge and strategic insight needed to manage pharmacy benefits with confidence and cost efficiency. Earn up to twenty continuing education credits while advancing your fiduciary and professional competencies. The CPBS program is accredited by both SHRM and HRCI, making it a powerful addition to your professional development portfolio. Strengthen your career, deliver measurable results, and help your organization take control of pharmacy spend. Register today to join a growing network of professionals shaping the future of pharmacy benefits management.
